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Background: Familial partial lipodystrophy, Dunnigan variety, is a recognised autosomal dominant disorder which
is caused by heterozygous missense mutations in the lamin A/C gene. Dunnigan lipodystrophy is characterised by
a variable loss of fat from the extremities and trunk, as well as an excess of subcutaneous fat in the chin and
supraclavicular area. The associated metabolic abnormalities include: insulin resistance, diabetes, dyslipidaemia and
low leptin levels.
Case presentation: The authors studied the case of a 24-year-old caucasian pregnant woman, with a past medical
history of acute pancreatitis, combined dyslipidaemia and diabetes mellitus. At 7 weeks of pregnancy she was
referred to the outpatient endocrinology and obstetrics clinic for diabetes care. A physical examination revealed
that she presented a loss of fat from the extremities and trunk and also had an excess of subcutaneous fat in the
chin. Triglyceride levels were persistently high, and glycaemic control was only achieved through the administration
of high doses of insulin (1.8 U/Kg/day). Dunnigan lipodystrophy was suspected and thus a genetic study was
requested, which revealed the presence of c.1444C > T (p.Arg482Trp) heterozygote mutation in the lamin A/C gene.
Conclusion: This case is used to illustrate the importance of being able to recognise the clinical signs of this rare
lipodystrophic syndrome, which may cause potentially severe consequences, and also the difficulties in treating it
during pregnancy.
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Lipodystrophies constitute a rare, heterogeneous group
of metabolic disorders, which affect adipose tissue distri-
bution, characterised by varying degrees of body fat loss
and, in some instances, an abnormal localised accumula-
tion of subcutaneous fat [1-5]. These disorders can be
divided into ‘generalised’, or ‘partial’, depending on the
degree and pattern of fat loss. Moreover, the generalised
and partial divisions can be further partitioned into
inherited, or acquired, forms. Metabolic complications,
such as hypoleptinemia, marked insulin resistance, dia-
betes mellitus, dyslipidaemia and hepatic steatosis, are* Correspondence: sandra.belo@gmail.com
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verity is related to the extent of fat loss [1,3,6].
The main subtypes of inherited lipodystrophies are auto-
somal recessive generalised lipodystrophy, linked to muta-
tions of either BSCL2 or AGPAT2 genes [7,8], and
autosomal dominant partial lipodystrophy, which is caused
by mutations in the PPARG [9-11] or LMNA [12,13] genes.
The Dunnigan lipodystrophy variety, also known as fa-
milial partial lipodystrophy type 2 (FPLD2; OMIM151660),
is a rare autosomal dominant disease, with an estimated
prevalence of less than 1 in 10 million [3], which is caused
by mutations in the LMNA gene, which is located in
chromosome 1q21-22, encoding the nuclear proteins lamin
A and C [12-14]. Lamin A and C are members of the inter-
mediate filament protein family, and are required for nu-
clear lamina formation [15,16]. The mutant gene products
may disrupt interaction with chromatin or other nuclear
lamina proteins, resulting in abnormal differentiation andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 a and b Loss of adipose tissue from the extremities
and the trunk.
Figure 2 Abnormal deposition of adipose tissue on the chin.
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cluster in the carboxy-terminal immunoglobulin domain of
lamin A/C [3], and the majority of patients have heterozy-
gous missense mutations, affecting codon 482 on exon 8
[20-25]. FPLD2 patients are born with normal fat distribu-
tion and after puberty they lose subcutaneous fat from their
extremities, trunk and gluteal regions. Excess fat may be
redistributed to the face, neck, back, labia majora and
the abdominal cavity or abdominal organs, namely the
liver, which accounts for the high prevalence of hepatic
steatosis [26-28]. Skeletal muscle fibres in patients with
FPLD2 display significant hypertrophy [29]. These patients
also experience a multitude of metabolic complications,
including hyperlipidaemia, hypertriglyceridaemia and dia-
betes. FLPD2 women, in whom the disease is usually more
severe [30,31], are at high risk of having hyperandrogen-
ism, infertility, gestational diabetes, obstetrical complica-
tions and they require extra gynaecological and obstetrical
care [32].
The authors now move on to describe the case of a




The 24-year-old caucasian female patient had a past
medical history of acute pancreatitis, and experienced
her first episode at the age of 20, which was complicated
by superior mesenteric vein thrombosis. The second epi-
sode occurred at the age of 21. Combined dylipidemia
was diagnosed in this context and was initially treated
with a statin and fibrate, but without adequate control.
Niacinic acid was added, with improved control. Dia-
betes, classified as secondary to pancreatitis, was later
diagnosed at the age of 22, and was treated with insulin
since the beginning of its discovery. The patient was
subsequently referred to endocrinology appointments,
where hypercortisolism was suspected, but excluded.
She abandoned these appointments shortly after.
Her gynaecological and obstetric history was irre-
levant, and she had no previous history of menstrual
abnormalities, hyperandrogenism, or infertility.
During pregnancy
At 7 weeks of pregnancy, she was referred to the out-
patient endocrinology and obstetrics clinic, in the con-
text of her diabetes. A physical examination revealed
that she presented loss of fat from the extremities and
trunk (Figure 1a; 1b), excess of subcutaneous fat in the
chin, and apparent muscle hypertrophy (Figure 2). Ac-
cording to the patient, these features had been present
since early adolescence. No other typical clinical features
were observed during the physical examination, namely
hirsutism or acanthosis nigricans. As previously noted,the therapy for diabetes was insulin, with an initial total
dose of 106 U/day (1.8 U/Kg/day). The patient was also
treated with heparin and salmon oil. Statin, niacinic acid
and fenofibrate treatment had already been suspended at
the time pregnancy was confirmed. She presented good
Figure 3 Family pedigree.
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and triglyceride levels of 1566 mg/dL (reference value
<150 mg/dL), and so was prescribed treatment with
gemfibrozil 600 mg, twice a day. Considering her past
medical history, and the clinical and biochemical charac-
teristics, Dunnigan lipodystrophy was suspected, and a
genetic study for mutations of lamin A/C was requested.
The presence of exon 8 c.1444C > T (p.Arg482Trp) het-
erozygote mutation in the LMNA gene was revealed. No
other genes were sequenced.
At 12 weeks of pregnancy, the patient was admitted to
the emergency department with the diagnosis of acute
pancreatitis, with triglyceride levels of 9975 mg/dL. After
improvement of triglyceride levels provoked by fasting,
treatment began with fenofibrate 267 mg, once a day,
and the patient was discharged with triglyceride levels of
655 mg/dL. One week later, on re-evaluation, she pre-
sented triglyceride levels of 2965 mg/dL. Considering
the risk of a new episode of pancreatitis, the patient was
then admitted for metabolic control, centred on fasting.
After discharge, with triglyceride levels of 1086 mg/dL, a
rigorous dietary plan was prescribed, and treatment was
also started with Omacor® [highly purified omega-3 fatty
acid ethyl esters (3 g tid)] and Protifar® [high protein pow-
dered supplement (32 sp)]. Triglyceride levels remained
constantly between 1000 and 2000 mg/dL until the birth.
The birth was by dystocic delivery – caesarean section -
because of the failure of natural labour. The operation
proceeded without complications and the new-born, al-
though macrosomic (4675 g), presented no clinical signs
of having the disease, as was expected.After delivery
After delivery, the patient begun regular evaluation dur-
ing endocrinology appointments and returned to statin
(rosuvastatin 20 mg), cholestyramine (4000 mg once a
day) and fibrate (fenofibrate 267 mg once a day) treat-
ment, with suboptimal triglyceride levels control (trigly-
ceride levels of 882 mg/dL). For diabetes treatment,
metformin was added to insulin, with good glycaemic
control (HbA1c < 7%).Family history
With regards to her family medical history, the patient
has 3 healthy brothers and a healthy father. However her
mother has type 2 diabetes mellitus, hypertriglyceridae-
mia and, according to the patient, she also has the same
fat distribution pattern. No history of pancreatitis is
known.
Medical evaluation and a genetic study, if appropriate,
was offered to all close relatives, but not one agreed to
be studied (Figure 3).The new-born was referred for genetic appointments,
in order to be studied for the presence of the mutation,
but this has not been performed yet.
Discussion
The present case illustrates the importance of early diag-
nosis of FPLD2, as well as the challenges faced by med-
ical professionals when prescribing treatment for FPLD2
during gestation, especially considering the limitations
imposed on treatment options during pregnancy.
Our patient has demonstrated the typical Dunnigan-
variety fat distribution since early adulthood. Before be-
ing pregnant, she also experienced two acute and severe
episodes of pancreatitis, which were secondary to ex-
tremely high triglyceride levels. As occurs in some pa-
tients, she was erroneously suspected of having Cushing
syndrome, but this hypothesis was excluded.
Despite these clinical manifestations, FPLD2 was only
diagnosed during pregnancy. The diagnosis was con-
firmed by a genetic study. Mutations of the codon 482
of the LMNA gene account for the majority of cases re-
ported [20-24,33-35], and, although this residue is trad-
itionally considered a mutational hot spot for FPLD2,
other mutations in exon 8 (codon 465, 466, 485 and
486) and in exon 11 (codon 582, 583 and 584) have been
recorded [20,33,36].
Lack of fertility and obstetrical complications are fre-
quent with FPLD2. Vantyghem et al. reported a preva-
lence of polycystic ovarian syndrome of more than 50%,
of infertility close to 30%, miscarriages of 50%, gesta-
tional diabetes of at least 30%, and preeclampsia and
foetal death of over 10% [25,32]. Contrary to these
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ovarian syndrome, nor any signs of hyperandrogenism,
and presented no difficulties in conceiving.
There is no specific treatment for FPLD2, and patients
are prone to develop acute pancreatitis, long-term com-
plications of diabetes, liver steatosis and cirrhosis, and
also accelerated atherosclerosis.
Currently, the insulin-sensitizing strategy uses lifestyle
modifications (diet, physical activity) as a first line of ap-
proach. Metformin or glitazones add some benefit when
lifestyle modifications alone are not sufficient. However,
many patients do not achieve adequate glycaemic con-
trol with oral antidiabetic medications, and most require
high insulin doses [37-39].
Hypertriglyceridaemia is often resistant to conven-
tional treatment. Fibric acid derivatives (PPARα agonists)
can be helpful, as well as high-dose omega − 3 polyunsat-
urated fatty acids. With some patients, low-dose statins,
which also inhibit prelamin A farnesylation, can be
added to reduce non-HDL-cholesterol levels [37].
Regarding adipocytokine replacement, the use of re-
combinant leptin in hypoleptinemic patients with lipody-
strophies gives very promising results, with marked
improvement in hyperglycaemia, hypertriglyceridemia,
and hepatic steatosis [40-43]. Leptin therapy reduces ap-
petite and causes weight loss, which contributes to redu-
cing metabolic complications. In addition to its main
effects, leptin also reduces ectopic lipid deposition in the
liver and muscle [44]. However, the effects of leptin are
less significant in patients with partial lipodystrophies
and other laminopathies, than in those with generalised
lipodystrophies [41]. In this context, the FDA has re-
cently approved metreleptin (Myalept®) treatment, but
only for patients with generalised, inherited and ac-
quired, lipodystrophies [45]. This approval was based on
results from an NIH open-label, single-arm study of 48
patients with congenital, or acquired generalized lipody-
strophy, who also had diabetes mellitus, hypertriglyc-
eridemia, and/or elevated levels of fasting insulin [46].
However, even though leptin replacement seems to be
the ideal treatment for metabolic complications in
FPLD2 patients, metreleptin is not yet commercially
available for these patients. Metreleptin is a pregnancy
category C treatment, so it should only be used if the
forecast benefit justifies the potential risk for the foetus.
At pregnancy conventional anti-dyslipidemic therap-
ies – such as statins, niacinic acid and some fibric acid
derivates – and some oral antidiabetic medications are
contraindicated, or at least, not recommended. Adding
to these limitations, normal pregnancy is characterised
by a 2 to 4-fold increase in plasma triglyceride concen-
tration, and also increased insulin resistance [47]. These
changes, which are well tolerated by most women with
normal baseline triglyceride levels and no compromisedmetabolic pathways, do however constitute an increased
risk of pancreatitis for women with FPLD2, mainly dur-
ing a period of life when treatment options are limited.
On account of the risk of pancreatitis, our patient was
submitted to an alternative treatment, using highly puri-
fied omega-3 fatty acid ethyl esters [48], and a high pro-
tein powdered supplement combined with fenofibrate,
after discussion of the possible risks involved.
Conclusion
This case illustrates the importance of a timely diagnosis
of FPLD2 in order to avoid severe, and possible life-
threatening consequences, such as pancreatitis. The au-
thors intend also to highlight the challenges involved
when confronting this condition in pregnant women.
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